Bausch + Lomb Corp Q2 2026 Earnings Release

Bausch + Lomb Corporation announced its second-quarter 2026 financial results, reporting total revenues of $1.394 billion, a 9% increase as reported and an 8% increase on a constant currency basis compared to the second quarter of 2025. The company experienced broad-based growth across all segments, with double-digit revenue growth in Surgical and Pharmaceuticals. Key highlights include a 175% reported revenue growth in premium intraocular lenses (IOLs) and strong performance from MIEBO® and XIIDRA®. The company reported a GAAP Net Loss attributable to Bausch + Lomb Corporation of $14 million, an improvement from a $62 million net loss in the prior year quarter. Adjusted EBITDA was $241 million. Bausch + Lomb is raising its full-year 2026 guidance for both revenue and Adjusted EBITDA, now expecting full-year revenue between $5.440 billion and $5.540 billion.